What Attempta-ratiopharm Treats: Main Uses and Benefits

The primary therapeutic use of this medication is for managing symptoms related to physical discomfort and skin manifestations in women of reproductive age. Indications include conditions such as moderate to severe acne vulgaris related to androgen sensitivity and hirsutism (excessive unwanted hair growth). It is generally used in situations involving chronic androgen-driven symptoms that may not have been adequately addressed by other treatments, such as topical therapy.

It is relevant in contexts involving heightened systemic burden and where additional symptomatic support is needed, primarily for addressing androgen-dependent skin symptoms and menstrual cycle abnormalities associated with conditions like Polycystic Ovary Syndrome (PCOS). This application is relevant in scenarios that involve managing symptoms related to systemic imbalance and providing oral contraception.

“It provides support that helps ease the overall symptom burden when dealing with persistent androgenic manifestations.”

The medication may help address groups of symptoms that may become less disruptive, assisting with maintaining functional stability and contributing to improved comfort during symptomatic periods.

Quick Fact: Relevant for Androgen-Driven Symptoms

This medication is commonly used to help with pronounced symptoms that interfere with daily functioning, supports patients during episodes of heightened discomfort related to systemic imbalance.

Regulatory References

1. European Medicines Agency (EMA) guidance on cyproterone-ethinylestradiol medicines

Attempta-ratiopharm (containing Cyproterone and Ethinylestradiol) is an anti-androgen and combined hormonal product. Its eligibility profile is strictly defined by regulatory bodies, primarily for women of childbearing age and is not indicated for use in children before menarche or in women after menopause.

Contraindicated Populations

The medicine must not be used by women who have or have had a blood clot (venous or arterial thrombosis), or who have conditions that significantly increase this risk. These conditions include:

• A known hereditary or acquired predisposition for thrombosis (e.g., specific clotting factor deficiencies).
• Severe, uncontrolled hypertension or severe dyslipoproteinaemia.
• Liver disease (current or history of severe hepatic disease or liver tumours).
• A current or history of meningioma.
• Undiagnosed vaginal bleeding or known hypersensitivity to any component.

Eligibility Constraints

• Pregnancy: Use is contraindicated and must be stopped immediately if pregnancy occurs.
• Lactation/Breastfeeding: Use is not recommended.
• Age: Not indicated for use in girls before menarche or in women after menopause.

The regulatory documentation requires discontinuation of the medicine prior to and during periods of prolonged immobilization, such as major surgery, due to the increased risk of venous thromboembolism.

Attempta-ratiopharm Interactions with other medicines and products

Official regulatory information identifies specific categories of substances that may alter the effectiveness or clearance of Attempta-ratiopharm, or whose own exposure may be modified by this combination.

Interaction Classifications and Restrictions

Pharmacokinetic and Exposure Alterations

Interactions involving the active ingredients (Cyproterone/Ethinyl Estradiol) are primarily pharmacokinetic, affecting drug concentrations:

• Enzyme Inducers: Substances like anticonvulsants (e.g., carbamazepine, phenytoin), certain anti-infectives (e.g., rifamycins, griseofulvin), and the herbal product St. John's wort are documented to accelerate the metabolism of Attempta-ratiopharm, officially leading to a decrease in the plasma concentration of the hormones.
• Clearance Modification: Attempta-ratiopharm is documented to affect the clearance rate of other medications. This can lead to altered plasma concentrations for co-administered drugs such as corticosteroids (e.g., prednisolone) and certain benzodiazepines (e.g., lorazepam, temazepam).

Other Documented Interactions

• The hormonal components may officially interfere with the results of certain laboratory tests, including those for blood clotting factors and thyroid function.

The mechanism of action of Attempta-ratiopharm is centered on its active ingredient, filgrastim, a recombinant form of Granulocyte-Colony Stimulating Factor (G-CSF). Filgrastim functions as an agonist by binding directly to and activating the G-CSF Receptor (G-CSF R), which is prominently expressed on hematopoietic cells, including myeloid progenitors, in the bone marrow. This receptor engagement triggers the dimerization of the receptor and the subsequent activation of the intracellular JAK/STAT signal transduction pathway. This cascade transmits a proliferative signal to the cell nucleus, promoting the transcription of anti-apoptotic genes and factors necessary for myeloid cell growth. The resulting biological process is the accelerated proliferation, differentiation, and maturation of neutrophil precursors. This stimulation of the myeloid lineage facilitates the rapid release of mature neutrophils from the bone marrow into the peripheral circulation, resulting in a significant increase in the Absolute Neutrophil Count (ANC).

Attempta-ratiopharm is designed exclusively for oral administration as a fixed-combination coated tablet. The standard dosage involves taking one tablet daily at approximately the same time each day, a procedural step essential for consistent administration. The tablet may be taken with or without food.

Dosing Schedule and Cycle

The medication follows a structured 28-day cyclic regimen. Users take one active tablet (containing 2 mg cyproterone acetate and 0.035 mg ethinyl estradiol) every day for 21 consecutive days. This is followed by a 7-day tablet-free interval, after which the next pack is started on schedule. The tablets must be swallowed whole and taken in the sequence indicated on the blister pack to maintain the integrity of the cycle.

Duration and Missed Doses

Treatment should be continued for a minimum duration; time to symptom relief is typically at least three months. Standard clinical practice involves discontinuation and re-evaluation 3 to 4 cycles after the symptoms have completely resolved. The continuation of the regimen requires a periodic assessment by a prescribing physician.

If a dose is forgotten, it must be taken as soon as it is remembered. If the delay is less than 12 hours from the usual time, the regimen's effect is maintained, and subsequent tablets should be taken at the usual time. If the tablet is missed by more than 12 hours, the missed tablet should be discarded, and an additional barrier method must be used for the next seven days of tablet-taking while the current pack is finished. The medicine is indicated only for women of reproductive age.

Research Evidence Overview: Attempta-ratiopharm Studies

The research for Attempta-ratiopharm (Cyproterone/Ethinyl Estradiol) is documented in clinical studies and regulatory assessments, primarily focusing on its use in women experiencing symptoms that are androgen-dependent. The evidence helps describe the patterns observed in patients with certain skin and hair conditions.

Evidence for Use in Moderate to Severe Acne Vulgaris

Research examining this combined medication for moderate to severe acne vulgaris includes Randomized Controlled Trials (RCTs) and systematic reviews. These studies focused on women of reproductive age, often including those who had previously used other common topical or systemic treatments. Researchers typically studied outcomes related to skin irritation by measuring the change in the number of acne lesions and applying standardized clinical severity scales. Findings describe patterns observed in these studies, where measurements related to lesion counts evolved over the course of the treatment period.

However, long-term outcomes are not fully established; for instance, the durability of the patterns observed in the studies after administration is stopped is not well characterized by available research. Research primarily consists of studies with short- to intermediate-term follow-up.

Evidence for Use in Hirsutism (Excessive Hair Growth)

The research was studied for hirsutism and involves open-label studies and comparative trials, often including women with Polycystic Ovary Syndrome (PCOS). Due to the natural hair growth cycle, trials required extended follow-up durations, often six to twelve months or longer. Studies monitored outcomes related to measured differences in hair growth, using objective tools such as the Ferriman-Gallwey score. Studies report that the patterns monitored in the studies evolved gradually, and findings indicate that the patterns were observed during the continuous administration of the preparation.

Evidence Gaps and Limitations

Data for certain groups, such as adolescents or women with specific coexisting metabolic conditions beyond PCOS, are still insufficient or come from smaller, non-randomized studies. The results apply only to the populations studied and may not reflect the outcomes for all women. Research highlights that the evidence quality varies across studies, particularly in older trials, due to differing methodologies and grading scales.

Key Studies & References

1. Cyproterone acetate: new advice to minimise risk of meningioma (GOV.UK Drug Safety Update)
2. Hirsutism: Evaluation and Treatment (SOGC Guideline No. 444)

Common questions about Attempta-ratiopharm (FAQ)

Q: What are the official guidelines about stopping Attempta-ratiopharm?

Regulatory guidance suggests the medicine should be re-evaluated by a prescribing physician approximately three to four cycles after the symptoms being treated have completely resolved. Regulatory documents state that the medicine should be stopped prior to and during periods of prolonged immobilization. The specific procedure for cessation should be discussed with a healthcare provider.

Q: Does Attempta-ratiopharm need to be taken at a specific time of day?

Official product information instructs that the tablets should be taken at approximately the same time each day. This approach is intended to promote a consistent daily drug level, as required for the treatment's established use.

Q: Does Attempta-ratiopharm have different brand names in other countries?

Attempta-ratiopharm contains the active ingredients of the generic formulation known as Co-cyprindiol. This combination of cyproterone and ethinyl estradiol is marketed under various brand names in different regions globally.

Q: What evidence exists about Attempta-ratiopharm's use over an extended period?

The available clinical research assessed by regulatory bodies largely focuses on short- to intermediate-term follow-up. Official documentation indicates that the long-term patterns and the durability of the observed effects, particularly after the administration is stopped, are not fully characterized by the available research.

Q: Can Attempta-ratiopharm be used by older adults?

Attempta-ratiopharm is strictly indicated for women of reproductive age. According to official eligibility constraints, the medicine is not indicated for use in women after menopause.

Q: Is Attempta-ratiopharm suitable for children or adolescents?

Official guidance states that the medicine is not indicated for use in girls before menarche, which is the start of menstruation. While use is not indicated before menarche, the determination of suitability for adolescents who have started menstruating is a clinical decision.

Q: Do I need a special prescription or monitoring for Attempta-ratiopharm?

As a hormonal product, Attempta-ratiopharm is a prescription-only medicine. Regulatory documentation requires a periodic clinical assessment by a physician. This monitoring helps track potential risk factors and health status as described in the official warnings and precautions.

Q: Is it normal to feel a change in appetite after starting Attempta-ratiopharm?

Official patient information lists changes in appetite (either increase or decrease) and weight changes (gain or loss) as potential side effects associated with this type of combined hormonal medicine.

Q: What is the expected duration of the medicine's effect after taking a single dose?

Pharmacokinetic data describes that one of the main active ingredients, cyproterone acetate, has a terminal half-life of approximately 42 hours. This suggests the active components remain in the system for a significant period following a single dose.

Q: Are there known interactions between Attempta-ratiopharm and herbal supplements?

Yes, regulatory documents specifically identify the herbal product St. John's wort (Hypericum perforatum) as a substance that can reduce the effectiveness of Attempta-ratiopharm by speeding up the drug's breakdown in the body.

Q: How does the medicine’s classification relate to its potential for misuse?

Attempta-ratiopharm is a prescription-only medicine classified as a combined hormonal product. It is not listed as a scheduled narcotic or controlled substance in major regulatory listings for the purpose of misuse classification.

Q: What is the process for reporting a suspected side effect of Attempta-ratiopharm?

Patients are advised in regulatory documents to discuss any suspected side effects with their doctor or pharmacist. Additionally, national regulatory agencies provide dedicated systems, such as the FDA MedWatch or the MHRA Yellow Card Scheme, for the direct reporting of adverse drug reactions.

Q: Do official sources describe any specific emotional changes linked to Attempta-ratiopharm?

Yes, official regulatory labeling lists mood changes and depressive mood among the commonly reported side effects. These effects are often noted during the initial period of treatment.

Q: Is it necessary to have routine check-ups while taking Attempta-ratiopharm?

Official regulatory guidance requires patients to undergo periodic clinical assessments by a physician. This monitoring helps identify major risks associated with combined hormonal preparations, such as blood pressure changes and factors for venous thromboembolism.

Q: Is Attempta-ratiopharm available in different forms (e.g., tablet, capsule)?

Attempta-ratiopharm is supplied solely as a coated tablet intended for oral administration. It is not available in other forms such as capsules or injections.

Q: What factors might influence the way a patient responds to Attempta-ratiopharm?

Official documentation states that a patient's risk profile is influenced by pre-existing conditions and lifestyle factors. These include a patient's age (particularly over 35), smoking status, obesity, and a personal or family history of thrombosis or high blood pressure.

Q: Is there any information about Attempta-ratiopharm affecting blood pressure?

Official labeling explicitly states that an increase in blood pressure has been reported in women using combined hormonal preparations like this one. Regulatory guidance requires that blood pressure be monitored during the course of the treatment.

Q: How is Attempta-ratiopharm typically packaged?

The medicine is typically supplied in blister packs containing 21 active tablets, designed to support the structured 28-day cyclic regimen. These packs are commonly supplied in multi-cycle units, such as 1 or 3 cycles.

Q: What happens if Attempta-ratiopharm is taken with caffeine?

Available data suggests that the ethinyl estradiol component may slow the metabolism of caffeine in the body. This interaction can be associated with increased caffeine exposure and associated effects.

Q: What is the information regarding Attempta-ratiopharm and products containing alcohol?

While core labeling often does not detail a major, acute contraindication with alcohol, the metabolism of hormonal components may be influenced by alcohol consumption. Therefore, no clinically significant drug-food/alcohol interaction that alters effectiveness is generally listed in core regulatory labeling.

Q: Are there reports of Attempta-ratiopharm interacting with common pain relievers?

Some regulatory-sourced information notes that the concentration of certain common pain relievers, such as acetaminophen, can be increased when combined with cyproterone acetate. The concentration of the medicine's own components may also be affected by certain pain relievers.

Q: Where can I find the official patient information leaflet (PIL) for Attempta-ratiopharm?

The official Patient Information Leaflet (PIL) or similar patient-facing regulatory document can be found by searching the websites of the relevant national drug authorities. These include Health Canada, the European Medicines Agency (EMA), or the MHRA in the UK.

Q: Is Attempta-ratiopharm approved for all conditions it is sometimes mentioned for online?

Regulatory approval for Attempta-ratiopharm is specifically limited to the treatment of moderate to severe acne and hirsutism linked to androgen sensitivity in women of reproductive age, and for contraception in this population. Uses beyond these indications are considered off-label and are not supported by the official authorized use.

Q: Can individuals with kidney conditions use Attempta-ratiopharm?

The official product information suggests caution for individuals with certain kidney conditions, such as severe chronic kidney disease, due to potential associated risks and the drug's metabolism. Use should be determined by a healthcare provider.

Q: Does Attempta-ratiopharm interact with common cold or flu medications?

Some components found in common cold or flu treatments, such as certain analgesics (like acetaminophen) or older antibiotics, are documented to interact with the hormonal components of this medicine. These interactions may alter the concentration of either drug.

Q: Can people with a history of anxiety use Attempta-ratiopharm?

Official documentation notes that the medicine is associated with mood changes and depressive mood. Individuals with a history of mental health conditions, including anxiety or depression, are often identified as a group for whom close medical monitoring may be appropriate during treatment.

How to Store and Dispose of Attempta-ratiopharm?

Attempta-ratiopharm (cyproterone acetate and ethinylestradiol) has specific storage and disposal requirements defined by regulatory labeling to maintain its stability and ensure safety.

Storage Requirements

Disposal Instructions

Unused or expired tablets must not be thrown away with household trash or disposed of via wastewater, as these methods can harm the environment. Patients are instructed to consult a pharmacist for guidance on proper local disposal methods, which helps protect natural resources.